Sunshine Guojian's Novel IL-4Rα Antibody Therapy Advances with NDA Acceptance

Stock News02-25

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has announced the receipt of an acceptance notice from the National Medical Products Administration. The notice confirms that the New Drug Application for the company's recombinant anti-IL-4Rα humanized monoclonal antibody injection, with the research code SSGJ-611, has been accepted for review. According to the announcement, SSGJ-611 is an anti-IL-4Rα monoclonal antibody that was independently developed, designed, screened, and humanized by the company, featuring a novel amino acid sequence. By specifically binding to IL-4Rα, SSGJ-611 blocks signaling from both IL-4 and IL-13, thereby alleviating conditions such as atopic dermatitis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170954211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170954211","market":"sh","top_or_hot":-1,"title":"Sunshine Guojian's Novel IL-4Rα Antibody Therapy Advances with NDA Acceptance","media":"Stock News","content":"<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has announced the receipt of an acceptance notice from the National Medical Products Administration. The notice confirms that the New Drug Application for the company's recombinant anti-IL-4Rα humanized monoclonal antibody injection, with the research code SSGJ-611, has been accepted for review. According to the announcement, SSGJ-611 is an anti-IL-4Rα monoclonal antibody that was independently developed, designed, screened, and humanized by the company, featuring a novel amino acid sequence. By specifically binding to IL-4Rα, SSGJ-611 blocks signaling from both IL-4 and IL-13, thereby alleviating conditions such as atopic dermatitis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunshine Guojian's Novel IL-4Rα Antibody Therapy Advances with NDA Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunshine Guojian's Novel IL-4Rα Antibody Therapy Advances with NDA Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-25 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has announced the receipt of an acceptance notice from the National Medical Products Administration. The notice confirms that the New Drug Application for the company's recombinant anti-IL-4Rα humanized monoclonal antibody injection, with the research code SSGJ-611, has been accepted for review. According to the announcement, SSGJ-611 is an anti-IL-4Rα monoclonal antibody that was independently developed, designed, screened, and humanized by the company, featuring a novel amino acid sequence. By specifically binding to IL-4Rα, SSGJ-611 blocks signaling from both IL-4 and IL-13, thereby alleviating conditions such as atopic dermatitis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1170954211","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170954211","pubTimestamp":1772026093,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has announced the receipt of an acceptance notice from the National Medical Products Administration. The notice confirms that the New...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688336":"三生国健","BK0239":"医药制造"},"translate_title":"三生国健新型IL-4R α抗体疗法获NDA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688336":1},"content_text":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) has announced the receipt of an acceptance notice from the National Medical Products Administration. The notice confirms that the New Drug Application for the company's recombinant anti-IL-4Rα humanized monoclonal antibody injection, with the research code SSGJ-611, has been accepted for review. According to the announcement, SSGJ-611 is an anti-IL-4Rα monoclonal antibody that was independently developed, designed, screened, and humanized by the company, featuring a novel amino acid sequence. By specifically binding to IL-4Rα, SSGJ-611 blocks signaling from both IL-4 and IL-13, thereby alleviating conditions such as atopic dermatitis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170954211","isCrawlerRequest":true}